- Conditions
- Bronchopulmonary Dysplasia
- Interventions
- MagniXene, hyperpolarized 129Xe MRI
- Combination Product
- Lead sponsor
- Xemed LLC
- Industry
- Eligibility
- Up to 1 Year
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 41
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Hyperpolarized Xe129
- Drug
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Pulmonary, Pneumonia, Hematopoietic System--Cancer
- Interventions
- 29-XeMRI imaging
- Device
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Scleroderma
- Interventions
- MRI, Hyperpolarized Xe129, HRCT
- Diagnostic Test · Drug
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Healthy
- Interventions
- Hyperpolarized Xe129
- Drug
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 25 Years to 35 Years
- Enrollment
- 260 participants
- Timeline
- 2023 – 2027
- U.S. locations
- 6
- States / cities
- Chicago, Illinois • Iowa City, Iowa • Kansas City, Kansas + 2 more
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Anoro Ellipta, Arnuity Ellipta
- Drug
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2028
- U.S. locations
- 1
- States / cities
- Keswick, Virginia
- Conditions
- Severe Asthma, COPD, Non-CF Bronchiectasis, Cystic Fibrosis (CF)
- Interventions
- Hyperpolarized 129 Xenon
- Combination Product
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Bronchiolitis Obliterans
- Interventions
- Hp 129Xenon
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 6 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Lung Transplant Rejection
- Interventions
- Sub study (Active): Two Lung MRI study with two navigational Bronchoscopy, Hyperpolarized Xenon129
- Diagnostic Test · Drug
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2029
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Radiation Injury
- Interventions
- Hyperpolarized 129-Xenon gas, MRI
- Drug · Device
- Lead sponsor
- Bastiaan Driehuys
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2022
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Asthma, COPD, Interstitial Lung Disease, Cystic Fibrosis, Pulmonary Hypertension, Pulmonary Infection, Other Lung Disease
- Interventions
- Hyperpolarized Xe129
- Drug
- Lead sponsor
- Mario Castro, MD, MPH
- Other
- Eligibility
- 3 Years and older
- Enrollment
- 260 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2028
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Electronic Cigarette Related Lung Damage
- Interventions
- Hyperpolarized xenon 129, Cardiopulmonary Stress Test, Pulmonary Function Test, Chest CT
- Drug · Diagnostic Test
- Lead sponsor
- Y. Michael Shim, MD
- Other
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2032
- U.S. locations
- 2
- States / cities
- Durham, North Carolina • Charlottesville, Virginia
- Conditions
- Severe Asthma
- Interventions
- Hyperpolarized Xenon 129
- Combination Product
- Lead sponsor
- Bastiaan Driehuys
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Lung Transplant Rejection
- Interventions
- Hyperpolarized 129-Xenon (MagniXene) MRI of the lung
- Combination Product
- Lead sponsor
- Xemed LLC
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Albuterol Sulfate, 2.5 Mg/3 mL (0.083%) Inhalation Solution, Vibrating Mesh Nebulizer, Metered Dose Inhaler, Jet Nebulizer
- Drug · Device
- Lead sponsor
- Polarean, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Hyperpolarized 129 Xenon Gas Comparing Idiopathic Pulmonary Fibrosis (IPF) Treatment
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Lung Cancer
- Interventions
- HP 129Xe MRI
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Xenon129 MRI imaging, Gadolinium MRI, Advair (250mcg/50mcg) one puff twice a day
- Drug
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Pulmonary Vascular Disease
- Interventions
- GE-141, Hyperpolarized 129Xenon gas, MRI
- Drug · Device
- Lead sponsor
- Bastiaan Driehuys
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- HSCT, Lung Transplant Recipient
- Interventions
- Hyperpolarized 129 Xenon
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- Not listed
- Enrollment
- 550 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2030
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Pulmonary Arterial Hypertension, Idiopathic Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension Associated With Connective Tissue Disease (Disorder), Connective Tissue Diseases
- Interventions
- 129Xe Hyperpolarized
- Drug
- Lead sponsor
- Bastiaan Driehuys
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Pulmonary Vascular Disease
- Interventions
- Hyperpolarized 129Xenon gas
- Drug
- Lead sponsor
- Bastiaan Driehuys
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- ILD
- Interventions
- Xenon-129
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 78 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Hyperpolarized Xe129
- Drug
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia